CordenPharma to build €500M Swiss peptide plant, generating 300 new jobs
CDMO CordenPharma plans to spend half of its €1 billion strategic peptide investment on a new production facility outside of Basel, Switzerland. The plant, which is slated to kick off commercial operations in the first half of 2028, will be able to tackle both GLP-1 and non-GLP-1 peptide projects, CordenPharma said.
CDMO CordenPharma plans to spend half of its €1 billion strategic peptide investment on a new production facility outside of Basel, Switzerland. The plant, which is slated to kick off commercial operations in the first half of 2028, will be able to tackle both GLP-1 and non-GLP-1 peptide projects, CordenPharma said.
